Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
1.745
-0.075 (-4.12%)
Nov 21, 2024, 2:13 PM EST - Market open
Immix Biopharma Employees
As of December 31, 2023, Immix Biopharma had 17 total employees, including 14 full-time and 3 part-time employees. The number of employees increased by 6 or 54.55% compared to the previous year.
Employees
17
Change (1Y)
6
Growth (1Y)
54.55%
Revenue / Employee
n/a
Profits / Employee
-$1,287,696
Market Cap
48.00M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17 | 6 | 54.55% |
Dec 31, 2022 | 11 | 9 | 450.00% |
Dec 31, 2021 | 2 | - | - |
Related Stocks
Company Name | Employees |
---|---|
111, Inc. | 1,520 |
LakeShore Biopharma | 758 |
BGM Group | 298 |
Cytosorbents | 186 |
Enzo Biochem | 136 |
Precision BioSciences | 109 |
CollPlant Biotechnologies | 75 |
Kronos Bio | 63 |
IMMX News
- 7 weeks ago - Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 - GlobeNewsWire
- 2 months ago - Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board - GlobeNewsWire
- 3 months ago - Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - GlobeNewsWire
- 4 months ago - California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) - GlobeNewsWire
- 4 months ago - Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201 - GlobeNewsWire
- 5 months ago - Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum - GlobeNewsWire
- 6 months ago - Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation - GlobeNewsWire
- 7 months ago - Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma - GlobeNewsWire